ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results
  • All
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Adolescents and young adults
  • Advocacy
  • Anal cancer
  • Antioxidants
  • AYA
  • Bladder cancer
  • Blood cancers
  • Brain cancer
  • Breast cancer
  • Cancer care delivery
  • Caregiving
  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • ComboMATCH
  • Communication
  • COVID-19
  • DCIS
  • DCIS breast cancer
  • De-escalation
  • Esophagus cancer
  • Financial hardship
  • Gallbladder cancer
  • Gastroesophageal cancer
  • Geriatric oncology
  • GI cancer
  • Green tea
  • HAI chemotherapy
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Health equity
  • Hepatic arterial infusion chemotherapy.
  • HER2+ breast cancer
  • Hormone therapy
  • Imaging
  • Immune system therapy
  • Immunotherapy
  • Implementation science
  • In memory
  • Kidney cancer
  • Language
  • Late Effects
  • Leukemia
  • LGBTQ+
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Mantle cell lymphoma
  • Melanoma
  • Men's health
  • Mesothelioma
  • Minimal residual disease
  • MRI
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloma
  • National Clinical Trials Network
  • NCI-MATCH
  • Neuropathy
  • Non-Hodgkin lymphoma
  • Nose and sinus cancer
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient care
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penile cancer
  • Peripheral T-cell lymphoma
  • Personalized medicine
  • Personalized screening
  • Personalized treatment
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Radiation therapy
  • Rare cancer
  • Real-world data
  • Real-world evidence
  • Registry studies
  • Renal cell carcinoma
  • Research results
  • Sarcoma
  • Screening
  • Sexual and gender minorities
  • Side effects
  • Skin cancer
  • Smoldering multiple myeloma
  • Social genomics
  • Soft tissue sarcoma
  • Solid tumors
  • Squamous cell carcinoma
  • Surveillance
  • Survivorship
  • Symptom management
  • Symptom science
  • Targeted therapy
  • Throat cancer
  • Thyroid cancer
  • Triple-negative breast cancer
  • Tumor test
  • Upper tract urothelial cancer
  • Urothelial cancer
  • All
  • Diane Dragaud
  • ECOG-ACRIN Staff
  • Katie Heller
January 5, 2023
Crowd of women from behind
January 5, 2023
Categories
  • Trial Results

Trial Results: The TAILORx trial continues to provide reassurance that many women with early breast cancer can safely forego chemotherapy

The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
Do you like it?
0 Read more
January 5, 2023
Patient and doctor speaking in exam room
January 5, 2023
Categories
  • Trial Results

Trial Results: A recent ECOG-ACRIN study finds excellent results for patients with acute lymphoblastic leukemia (ALL)

Adding immunotherapy to standard chemotherapy keeps most patients in remission and improves their survival
Do you like it?
0 Read more
September 26, 2022
Research dictionary entry
September 26, 2022
Categories
  • Trial Results

Trial Results: ECOG-ACRIN research round-up – Fall 2022

Summaries of recently reported ECOG-ACRIN research results
Do you like it?
0 Read more
June 28, 2022
Research dictionary entry
June 28, 2022
Categories
  • Trial Results

Trial Results: ECOG-ACRIN research round-up – Summer 2022

Summaries of recently reported ECOG-ACRIN research results
Do you like it?
0 Read more
Prev page
123456
Next page

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc